Ozempic
WHO Endorses GLP-1 Drugs for Weight Loss in Major Policy Shift
Popular drugs like Ozempic are now a part of official global health recommendations from the World Health Organization to treat obesity.
Americans Are Conflicted on the Long-Term Effects of GLP-1s, Data Shows
While Americans see the benefits of GLP-1s, skepticism about relying on an injection to lose weight still runs deep, a new survey finds.
GLP-1s Are Most Popular in These US Cities, Report Finds
Search trends and survey data show where interest in weight loss drugs like Ozempic and Wegovy is surging in America.
Ozempic’s Biggest Fans? It’s Not Gen Z
A new survey from AlynMD reveals shifting attitudes toward weight loss medications like Ozempic and which generation is most on board.
New Partnership Brings WeightWatchers GLP-1 Program to UK
WeightWatchers partners with U.K.-based CheqUp to expand GLP-1 support, following news of its Chapter 11 and focus on long-term growth.
Zepbound Trumps Wegovy in Weight Loss Showdown, Study Finds
Zepbound helped patients lose more weight than Wegovy in a 72-week trial, with greater reductions in both body weight and waist size.
WeightWatchers Files for Chapter 11, Vows its ‘Here to Stay’
WeightWatchers has filed for Chapter 11 bankruptcy as part of a financial restructuring and a renewed focus on telehealth.
America’s GLP-1 Spending Soared From $14B to $72B in 5 Years
New data shows U.S. consumer spending on GLP-1 drugs like Ozempic, Wegovy and Mounjaro soared from $13.7B to $71.7B between 2018 and 2023.
The Foods Capturing the Wallet Share of GLP-1 Users
Weight-reducing drugs such as Ozempic and Wegovy are changing how Americans eat, paving the way for nutrition brands to make their mark.
Weight is Weighing on the Majority of Americans, Survey Finds
A new report from Hims & Hers underscores the urgency of weight loss for Americans as companies race to distribute weight loss medications.
